Abstract:BACKGROUND: TP53 mutations are common in breast cancer. There is currently no large-scale cohort study to investigate the TP53 landscape in breast cancer patients from China. The predictive value of TP53 mutations for the efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapy in breast cancer remains controversial. In the present study, we aimed to analyze the clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA (ctDNA) from breast cancer patients in China.METHODS: We retrospectively analyzed the clinical data and TP53 mutation features in ctDNA samples from 804 patients with metastatic breast cancer. TP53 mutations were detected by target region capture-based next-generation sequencing. The relationship between TP53 mutation status and disease-free survival (DFS) was analyzed in 444 patients with metastatic breast cancer. Moreover, the relationship between TP53 mutation status and progression-free survival (PFS) was analyzed in 55 HER2-positive patients treated with first-line trastuzumab-based therapy. Kaplan-Meier analysis was performed to estimate the survival curves of the different subgroups, and the log-rank test was used to compare the curves. A Cox regression model was used to estimate multivariable-adjusted hazard ratios and their 95% confidence intervals (CIs) associated with the DFS and PFS.RESULTS: Among the 804 investigated patients, 431 (53.6%) patients harbored TP53 mutations. TP53 mutations were differentially distributed among different molecular subtypes of breast cancer (P < 0.05). Patients with TP53 mutations had a shorter DFS than those with wild-type TP53 (hazard ratio = 1.32, 95% CI = 1.09-1.61, P = 0.005). TP53 mutations in exons 5-8 were associated with worse outcome (hazard ratio = 1.50, 95% CI = 1.11-2.03, P = 0.009). However, TP53 mutation status was not significantly associated with PFS in HER2-positive patients who received first-line trastuzumab-based therapy (P = 0.966). Interestingly, in the taxane combination group, patients with TP53 mutations exhibited longer PFS than those without TP53 mutations (hazard ratio = 0.08, 95% CI = 0.02-0.30, P < 0.001). However, in the non-taxane combination group, patients with TP53 mutations displayed shorter PFS than those with wild-type TP53 (hazard ratio = 4.84, 95% CI = 1.60-14.66, P = 0.005).CONCLUSIONS: TP53 mutations in exons 5-8 may be an independent prognostic marker for short DFS in patients with metastatic breast cancer. TP53 mutations had opposite effects on trastuzumab-treated patients treated with and without taxanes.

[Peripheral Blood Mutated P53 DNA and Its Clinical Value in Human Breast Cancer].

p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

Retracted: P53 Mutation in Plasma Dna and Its Prognostic Value in Breast Cancer Patients (retracted Article. See Vol 8, Pg 3027, 2002)

Detection of P53 Gene Mutation in Plasma of Patients with Gastric Cancer

Clinical Value of P_53 Gene Mutation in Bladder Cancer

Effects of plasma p53 gene mutation in the development and prognosis of non-small cell lung cancer

Clinical Biology Value of P53 Overexpression in Chinese Breast Cancer by Meta Analysis

[Detection of P53 Gene Mutation in Peripheral Blood in the Diagnosis of Patients with Lung Cancer].

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

[Comparison of Nuclear Accumulation of P53 Protein with Mutations in the P53 Gene on the Tissues of Human Breast Cancer].

Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis

Prognostic Significance of the Tumor Suppressor Protein P53 Gene in Childhood Acute Lymphoblastic Leukemia.

P53 Protein Expression Levels in Stage I Breast Cancer and Its Relationship to Clinico - Pathologic Parameters

Expression and Significance of P51 Gene in Breast Cancer

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China

The Presence of Serum Anti-p53 Antibodies from Patients with Invasive Ductal Carcinoma of Breast: Correlation to Other Clinical and Biological Parameters

[Clinical Significance of Mutant P53 Protein Expression in Lung Adenocarcinoma].

The Clinical Significance of Detection of P53 Gene Mutation in Patients with Lung Cancer

The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot

Cmar_a_298729 3303..3316

Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.